A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

NCT06383767 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

378

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: ESG401
DRUG: Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)

Sponsor

Qilu Pharmaceutical Co., Ltd.